{"id":61922,"title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.","abstract":"","date":"2014-05-16","categories":"Hemic and Lymphatic Diseases","split":"train","url":"http://www.ncbi.nlm.nih.gov/pubmed/24652992","annotations":[{"name":"Objectivity (philosophy)","weight":0.741915,"wikipedia_article":"http://en.wikipedia.org/wiki/Objectivity_(philosophy)"},{"name":"Brentuximab vedotin","weight":0.0297972,"wikipedia_article":"http://en.wikipedia.org/wiki/Brentuximab_vedotin"},{"name":"Lymphoma","weight":0.0158689,"wikipedia_article":"http://en.wikipedia.org/wiki/Lymphoma"}]}
